CME Group (CME) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Feb, 2026Executive summary
Achieved the most successful year in company history, with record annual revenue of $6.5 billion, up 6% year-over-year, and record volumes in 2025, continuing strong momentum into 2026.
Fifth consecutive year of record average daily volume, reaching 28.1 million contracts for the year, with broad-based growth across all asset classes and international markets.
Expanded product innovation, including Event Contracts and new crypto offerings, driving engagement from new retail and institutional clients.
Adjusted net income for the year was $4.1 billion, with adjusted diluted EPS of $11.20.
Q4 revenue reached $1.65 billion, with net income of $1.2 billion and diluted EPS of $3.24.
Financial highlights
2025 revenue reached $6.5 billion, up 6% year-over-year, with record revenues in five of six asset classes.
Adjusted net income was $4.1 billion, with adjusted EPS up 9% year-over-year to $11.20.
Market data revenue surpassed $800 million for the first time, up 13% year-over-year.
Full-year operating income was $4.2 billion, up from $3.9 billion in 2024.
Cash at year-end was $4.6 billion, including $1.3 billion in OSTTRA proceeds.
Outlook and guidance
2026 adjusted operating expenses (excluding license fees) expected to be ~$1.695 billion, reflecting core growth and investments in new initiatives.
Capital expenditures projected at $85 million; adjusted effective tax rate between 23.5%-24.5%.
Fee adjustments and market data changes expected to increase total revenue by 1%-1.5% on similar activity to 2025.
Focused on expanding access through U.S. Treasury clearing, 24/7 cryptocurrency trading, and prediction markets.
Plans to further increase average daily margin efficiencies for market users.
Latest events from CME Group
- Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Global growth, product innovation, and high margins drive record performance and shareholder returns.CME
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Record 2025 growth fueled by innovation, global reach, and strong capital efficiencies.CME
Investor presentation3 Mar 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026 - Record Q2 revenue, net income, and trading volumes, with growth in every asset class and strong margins.CME
Q2 20243 Feb 2026 - Strong volumes and global uncertainty drive growth focus in equities and credit, with regulatory vigilance.CME
Piper Sandler Global Exchange and Trading Conference 20241 Feb 2026